Multi-Year Follow-Up Study Validating the Clinical Value of Medigus' MUSE(TM) System for the Treatment of GERD To Be Presented at Digestive Disease Week 2014

Medigus Ltd. logo

-Additional Study Explores Future Applications for MUSE(TM) as a Combination Treatment for Achalasia-

OMER, Israel, April 29, 2014 (GLOBE NEWSWIRE) -- Medigus Ltd. (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and procedures, announced today that two presentations underscoring the clinical impact of the MUSE(TM) System (formerly the SRS(TM) System) and exploring future applications will be presented at the prominent Digestive Disease Week (DDW) annual meeting. DDW will take place from May 4-6, 2014, at McCormick Place, Chicago, IL, where Medigus will be exhibiting at booth #3042 throughout the conference.

MUSE(TM) is a device enabling a single endoscopist to conduct an incisionless procedure. The device performs a surgical anterior fundoplication with standard surgical staples in a less invasive way, helping enhance patient care and potentially increase hospital efficiency through lower costs and reduced hospital stays.

"We are excited to showcase these important studies supporting the MUSE(TM) System as a safe, efficient and less-invasive option for the treatment of GERD, one of the most common chronic diseases worldwide," said Chris Rowland, CEO, Medigus. "We look forward to educating the clinician community about minimally-invasive alternatives to long term PPI use that will enhance the care of GERD patients."

Key MUSE(TM) Poster Presentations at DDW
All data being presented during DDW is embargoed until the date and time of presentation, which is 8 a.m. CT for posters.

Tuesday, May 6, 8:00AM - 5:00PM | Tu1396 | Location: McCormick Place - South Hall

Longer Term Follow Up after Endoscopic Treatment of GERD with the Medigus SRS(TM) Endoscopic Stapling Device
Kessler, William R.; McNulty, Gail; Selzer, Don J.; Lehman, Glen A

Tuesday, May 6, 8:00AM - 5:00PM | Tu1595 | Location: McCormick Place - South Hall

Transoral treatment of Achalasia: Combining submucosal myothomy with transoral funduplication
Rosamaria, Bozzi; Roy-Shapira, Aviel; Schettino, Pietro; Cattaneo, Fabio; Pezzullo, Angelo M.; Cataneo, Domenico

Medigus Ltd. did not provide financial support for the above scientific sessions and did not influence the content in any way. However, research presented within these scientific sessions may have been supported by Medigus Ltd.

In addition, Medigus will be participating in the ASGE IT&T Learning Center's hands-on demonstration course on Tuesday, May 6, 10:30AM - 12:30PM.

About DDW

Digestive Disease Week® (DDW®) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 3 - 6, 2014, at McCormick Place, Chicago, Illinois. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at

About MUSE(TM)

MUSE(TM) is an intuitive endosurgical platform that consists of a single use surgical endostapler, equipped with a proprietary miniature camera, an ultrasonic sight and a range finder. The single operator system performs an anterior partial fundoplication with standard surgical staples in a less invasive way, compared to other surgical procedures.

About Medigus

Medigus is leading the transition from invasive gastric surgery procedures to less invasive, patient-friendly techniques through the development of minimally invasive endoscopic devices and procedures. The company's revolutionary MUSE(TM) System enables endoscopists and surgeons to treat gastroesophageal reflux disease (GERD), a chronic disease with increasing global prevalence, by performing a fundoplication procedure through the mouth. Unlike current fundoplication procedures, the MUSE(TM) system does not require abdominal incisions, which may result in shorter post-procedure recovery. The MUSE(TM) System (previously known as SRS(TM) System for transoral fundoplication) has received FDA clearance and CE mark. Medigus is traded on the TASE (Tel Aviv Stock Exchange). To learn more about the company's minimally invasive technology platform, please visit


Chantal Beaudry/Martyna Gawrych
Lazar Partners Ltd.

Miri Segal-Scharia
Hayden/ MS-IR LLC


Source:Medigus Ltd.